ATE409459T1 - Antigene zusammensetzungen - Google Patents

Antigene zusammensetzungen

Info

Publication number
ATE409459T1
ATE409459T1 AT03787793T AT03787793T ATE409459T1 AT E409459 T1 ATE409459 T1 AT E409459T1 AT 03787793 T AT03787793 T AT 03787793T AT 03787793 T AT03787793 T AT 03787793T AT E409459 T1 ATE409459 T1 AT E409459T1
Authority
AT
Austria
Prior art keywords
antigen
carbohydrate
parenteral
sublimation
administration
Prior art date
Application number
AT03787793T
Other languages
English (en)
Inventor
Velde V Vande
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE409459T1 publication Critical patent/ATE409459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03787793T 2002-08-13 2003-08-12 Antigene zusammensetzungen ATE409459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0218821.7A GB0218821D0 (en) 2002-08-13 2002-08-13 Novel compositions

Publications (1)

Publication Number Publication Date
ATE409459T1 true ATE409459T1 (de) 2008-10-15

Family

ID=9942239

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03787793T ATE409459T1 (de) 2002-08-13 2003-08-12 Antigene zusammensetzungen

Country Status (19)

Country Link
US (1) US20060051372A1 (de)
EP (1) EP1528914B1 (de)
JP (1) JP2006500358A (de)
KR (1) KR20050056965A (de)
CN (1) CN1674867A (de)
AT (1) ATE409459T1 (de)
AU (1) AU2003255440A1 (de)
BR (1) BR0313337A (de)
CA (1) CA2494002A1 (de)
DE (1) DE60323842D1 (de)
GB (1) GB0218821D0 (de)
IL (1) IL166526A0 (de)
IS (1) IS7671A (de)
MX (1) MXPA05001728A (de)
NO (1) NO20050543L (de)
PL (1) PL375590A1 (de)
RU (1) RU2005102589A (de)
WO (1) WO2004016241A1 (de)
ZA (1) ZA200500833B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
EP1697033B1 (de) * 2003-12-19 2011-04-13 Alk-Abelló A/S Verfahren zur kryogranulierung und lagerung von allergenen
ATE381945T1 (de) * 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
JP2008096503A (ja) * 2006-10-06 2008-04-24 Toshiba Corp 粉末状感光性組成物の製造方法、感光性組成物およびこの感光性組成物から形成された光記録媒体
BRPI0811228A2 (pt) * 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
WO2009050586A1 (en) * 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
US20160317646A1 (en) * 2013-12-19 2016-11-03 Crucell Holland B.V. Formulations for virosomes
WO2016138362A1 (en) * 2015-02-26 2016-09-01 The Board Of Trustees Of The University Of Arkansas Treatment vaccine for prostate cancer
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
DK3429618T5 (da) 2016-03-16 2024-09-16 Amal Therapeutics Sa Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin
DK3515476T3 (da) * 2016-09-21 2024-09-02 Amal Therapeutics Sa Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
WO2020016322A1 (en) * 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
KR20230013237A (ko) 2020-03-09 2023-01-26 다이나박스 테크놀로지 코퍼레이션 Tlr9 효능제를 포함하는 대상포진 백신
CN117100707A (zh) * 2023-10-19 2023-11-24 江苏瑞科生物技术股份有限公司 一种针对hpv免疫原性蛋白的冻干保护剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186908A (en) * 1962-08-16 1965-06-01 Parke Davis & Co Calcium lactobionate stabilization of labile antigenic virus vaccine materials
KR870700024A (ko) * 1984-07-12 1987-02-28 원본미기재 약, 비타민 또는 왁진의 근육내 주사용 제제
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations

Also Published As

Publication number Publication date
GB0218821D0 (en) 2002-09-18
IS7671A (is) 2005-01-27
JP2006500358A (ja) 2006-01-05
CN1674867A (zh) 2005-09-28
CA2494002A1 (en) 2004-02-26
WO2004016241A1 (en) 2004-02-26
NO20050543L (no) 2005-03-11
IL166526A0 (en) 2006-01-15
ZA200500833B (en) 2006-08-30
AU2003255440A1 (en) 2004-03-03
US20060051372A1 (en) 2006-03-09
EP1528914B1 (de) 2008-10-01
MXPA05001728A (es) 2005-05-27
BR0313337A (pt) 2005-06-14
PL375590A1 (en) 2005-11-28
DE60323842D1 (de) 2008-11-13
RU2005102589A (ru) 2005-10-10
EP1528914A1 (de) 2005-05-11
KR20050056965A (ko) 2005-06-16

Similar Documents

Publication Publication Date Title
DE60323842D1 (de) Antigene zusammensetzungen
ES2897659T3 (es) Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas
EP2709657B1 (de) Wärmestabile impfstoffzusammensetzungen und verfahren zu ihrer herstellung
ES2612741T3 (es) Proteínas de fusión proteína n de un virus de la familia paramyxoviridae-proteína de interés
EA200801374A1 (ru) Вакцина
ES2304960T3 (es) Vacuna combinada contra streptococcus pneumoniae y virus sincicial respiratorio (rsv).
AU3847801A (en) Proteosome influenza vaccine
KR20050084575A (ko) 백신의 개선 또는 백신에 관한 개선
Isibasi et al. Active protection of mice against Salmonella typhi by immunization with strain-specific porins
HUP0303278A2 (hu) Fagyasztva szárított pantoprazol készítmény, eljárás az előállítására és pantoprazol injekció
JP2007505033A5 (de)
WO2009108689A1 (en) Sugar glassified virus like particles (vlps)
CN106063933B (zh) 通用疫苗冻干保护剂及其应用
Eliasson et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus
KR20180043352A (ko) 다가 vlp 접합체
WO2018231706A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
Katsura et al. Novel bovine viral diarrhea virus (BVDV) virus-like particle vaccine candidates presenting the E2 protein using the SpyTag/SpyCatcher system induce a robust neutralizing antibody response in mice
CN103228293A (zh) 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
ES2558157T3 (es) Métodos para potenciar la capacidad adyuvante de las composiciones de vacunas
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
Payton et al. Lyophilized vaccine development
Kumar et al. Pandemic and Vaccines–The Case of Deadly Anthrax Infection, Vaccine Development and Evolution
CN101296705A (zh) 固体疫苗制剂
KR20210068429A (ko) 점막 애주번트
ATE473762T1 (de) Ein impfstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties